Peer-reviewed veterinary case report
Transvaginal mesh safety and outcomes for pelvic organ prolapse in
By Lo TS et al.·2026·Department of Obstetrics and Gynecology·View original on Europe PMC →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Transvaginal Mesh for pelvic organ prolapse in Taiwan (2004-2025): Outcomes and safety in the wake of the 2019 FDA licensing halt.
Plain-English summary
This study looked at the use of transvaginal mesh (a type of surgical mesh used to support pelvic organs) for fixing pelvic organ prolapse (when pelvic organs drop from their normal position) in Taiwan from 2004 to 2025. Researchers reviewed 96 studies and found that over 90% of patients had successful outcomes after one year, with many reporting improved quality of life. The newer types of mesh used had low rates of complications, and most issues that did arise were minor and manageable. The study concluded that transvaginal mesh remains a reliable option for treating pelvic organ prolapse, emphasizing the need for proper training and careful patient selection to minimize risks. Overall, the treatment was effective and showed promising results.
Abstract
<h4>Objective</h4>To review the evolution, outcomes and safety of transvaginal mesh (TVM) use for pelvic organ prolapse (POP) repair in Taiwan from January 2004 to May 2025.<h4>Materials and methods</h4>A systematic literature search in PubMed using MeSH terms "transvaginal mesh" AND "Pelvic organ prolapse", yielding 856 articles. Of these 96 Taiwanese studies were included, comprising 10 prospective trials, 1 meta-analysis, and the remainder retrospective studies. A total of 88 study cases involving various mesh types were analyzed.<h4>Results</h4>Objective cure rates exceeded 90% at 1-year across most mesh types, with significant improvements in quality of life measured by validated questionnaires (POPDI-6, IIQ-7, UDI-6, PISQ-12). Mesh extrusion rates with newer generation meshes (2019-2023) ranged from 0.8% to 4.8%. Most complications, such as urinary tract infections and voiding dysfunction, were minor and manageable. Surelift, Calistar-S and MIPS, the only currently approved meshes for transvaginal use in Asia, showed promising one-year cure rates, all exceeding 92%. Surelift demonstrated superiority more than native tissue repair at 5 years, with success rates of 89.1% vs. 64.4% (p = 0.002). Older age was associated with increased risk of voiding dysfunction and recurrence (HR 1.07, if > 64 years). Obesity did not increase mesh-related complications but has greater postoperative symptom burden. Concomitant MUS effectively reduced de novo stress urinary incontinence from 31.2% to 5%.<h4>Conclusion</h4>TVM continues to be a reliable and effective option for POP management. Taiwan's experience highlights the importance of proper training, patient selection, and surgical refinement in minimizing complications. Long-term follow-up and awareness of red-flag symptoms remains essential.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Europe PMC: https://europepmc.org/article/MED/42036180